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Abstract—Nitric oxide (NO) production and carbon monoxide (CO) production are increased in
inﬂammatory lung diseases. Although there are some pieces of evidence for hormonal modulation
by estrogen, little is known about exhaled NO and CO during the ovarian cycle. In 23 subjects, we
measured exhaled NO and CO by an online analyzer. Signiﬁcantly higher levels of exhaled NO
were found at the midcycle compared with those in the premenstrual period or during menstruation.
Higher levels of CO were after ovulation and reached a peak in the premenstrual phase. The lowest
levels of CO were observed in the ﬁrst days of the estrogen phase. In males, there was no signiﬁcant
variation in exhaled NO and CO. Exhaled NO and CO levels vary during the ovarian cycle in
women, and this fact should be taken into account during serial measurements of these markers in
the female population.
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INTRODUCTION
Nitric oxide (NO) and carbon monoxide (CO) may
be produced in increased amounts in various inﬂamma-
tory lung diseases [1, 2]. Exhaled nitric oxide is
increased in bronchial asthma [3], during upper respira-
tory tract viral infections [4], bronchiectasis [5], and
active ﬁbrosing alveolitis [6]. Exhaled CO is increased
in asthma [7], cystic ﬁbrosis [8], bronchiectasis [9], and
respiratory tract infections in normal subjects [10]. In
cystic ﬁbrosis, NO is lower compared in healthy subjects
possibly due to a reduced expression of inducible NO
synthase in the airways [11].
Both exhaled NO and CO are recognized as
markers of inﬂammation and tend to decrease during
steroid treatment, making this measurement of potential
value in monitoring lung inﬂammation [12].
Although little is known about the regulation of
airway NO and CO production, indirect evidence
suggests that it may be modulated by estrogen related
to the ovarian cycle in women. It has been noted that
asthma symptoms are less severe in midcycle when
estrogen to progesterone ratio in systemic blood is
highest. They worsen during menses when the ratio
goes down after ovulation [13]. Kharitonov et al. have
demonstrated that NO production is inﬂuenced by
cyclical hormonal changes in women. There was an
increase of more than 100% of peak NO at midcycle
[14]. Estrogen increases the expression of endothelial
NO synthase in a human bronchial epithelial cell line
through a process that involves the stimulation of
estrogen receptors and calcium inﬂux [15].
Little is known about exhaled CO during the
ovarian cycle. Endogenous production of carbon mon-
oxide is increased during the progesterone phase of the
ovarian cycle. This is correlated with an increased in red
cell catabolism and an increased in reticulocyte counts
[16]. An increased CO in subjects on contraceptive
drugs may also be related to the activity of progesterone
[17]. This increase in CO may be related to heme
oxygenase 1 (HO-1) activation by several stimulants
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554including hormones [17, 18]. Progesterone has been
shown to increase expression of HO-1 in myometrial
cells [19]. Also, endogenously generated NO induces the
expression of HO-1 in vascular endothelial and smooth
muscle cells [20]. This may provide protection against
oxidative stress to endothelium [21]. On the other hand,
CO can bind to the heme moiety of NOS and thus inhibit
NO production [22].
Since both NO and CO are increasingly used as
simple and noninvasive tools for monitoring airway
inﬂammation, standardization is important especially
when repeated measurements of exhaled NO and CO
are made in female subjects. For this reason, we
undertook a study of serial measurements of exhaled
NO and CO during ovarian cycle.
METHODS
Subjects
We included 15 healthy, nonsmoking, regularly
menstruating females, who were not taking any medi-
cations (including oral contraception; mean age, 34±
9 years). Eight healthy, nonsmoking age-matched males
(mean age, 34±3 years) comprised the control group.
All the subjects were recruited from staff members at the
Royal Brompton Hospital. A series of measurements
were performed on them at frequent intervals (days 1–6,
7–12, 13–19, 20–25, and 26–31; day 1 was the 1st day
of menstruation) during their ovarian cycle. Male
subjects also underwent similar serial measurements.
All subjects were asked to inhale room air at total lung
capacity and then to exhale slowly into a tube connected
directly to the NO and CO analyzer. All subjects signed
a consent form, and the study was approved by the local
Ethics Committee.
Exhaled NO measurements
Exhaled NO was measured by a chemilumines-
cence analyzer (model LR2000; Logan Research,
Rochester, UK) sensitive to NO from 1 to 5,000 ppb
(by volume) and with a resolution of 0.3 ppb which was
designed for online recording of exhaled NO, as
previously described [23]. The analyzer was calibrated
using certiﬁed NO mixtures (90 and 436 ppb) in
nitrogen (BOC Special Gases, Guilford, UK). Measure-
ment of exhaled NO was made by slow exhalation (5–
6 l/min) from total lung capacity for 20–30 s against a
resistance of 3±0.4 mmHg. Two successive recordings
were taken, and plateau values were used in all
calculations.
Exhaled CO measurement
ExhaledCOwasmeasuredusingachemiluminescence
analyzer (model LR2000; Logan Research, Rochester, UK)
sensitive to 1–500 ppm (by volume) CO adapted for online
recording. The subjects exhaled slowly at total lung capacity
with a constant ﬂow (5–6 l/min) against a resistance of 3±
0.4 mmHg over 20–30 s [24]. Two successive recordings
were made, and maximal values were used in all calcu-
lations. Ambient CO levels were recorded before each
measurement and subtracted from measured values.
Statistical analysis
Data are expressed as means±standard deviation.
Differences between exhaled NO and CO levels pro-
duced during particular phases of ovarian cycle were
compared with Kruskal–Wallis test.
RESULTS
Table 1 shows mean exhaled NO and CO levels
from men and women. Measurements were performed
during the ﬁrst visit. There were no signiﬁcant differ-
ences in either NO or CO levels between men and
women; however, the variability was greater in women.
There were no signiﬁcant differences between
repeated measurements in men (Table 2).
Exhaled NO changes in expired NO levels during
ovarian cycle are shown in Fig. 1. Signiﬁcantly greater
levels of exhaled NO were observed in the midcycle
compared with those in the ﬁrst third of progestational
phase and premenstrual period (6.8±2.17 versus 4.1±
1.18 and 4.3±1.6 ppb; p<0.001 and p<0.01, respec-
tively) and during menstruation (5.0±2.11 ppb; p<0.02).
Exhaled CO changes in exhaled CO levels in
relation to ovarian cycle are shown in Fig. 2. In contrast
to changes in exhaled NO levels, exhaled CO levels
Table 1. Exhaled Nitric Oxide (NO) and Carbon Monoxide (CO) Levels
in Sex Groups
Male (n=8) Female (n=15) p value
Age (year) 34±3 34±9 >0.05
NO (ppb) 5.08±1.23 5.36±3.6 >0.05
CO (ppm) 3.02±0.96 3.39±2.87 >0.05
Means±standard deviations are shown
555 Exhaled NO and CO During Ovarian Cyclewere not the highest in the midcycle (3.9±1.67 ppm).
Higher levels of exhaled CO were observed during the
ﬁrst third of progestational phase of the endometrial
cycle (after ovulation) and reached peak values in
premenstrual phase (4.4±1.9 and 5.9±3.28 ppm, respec-
tively), both signiﬁcantly higher than values obtained
from measurements done in other phases of the ovarian
cycle (p<0.05). These were followed by a decreased in
CO levels during menstruation with a signiﬁcant fall in
the ﬁrst days of the estrogen phase (3.6±2.87 and 3.1±
1.0 ppm, respectively).
No correlations between exhaled NO and CO levels
during ovarian cycle were found.
DISCUSSION
In this study, we have shown that exhaled NO
(ENO) and CO (ECO) levels vary during the ovarian
cycle. NO levels are highest in the midcycle and exhaled
CO is increased during premenstrual phase. Hormone-
mediated effects on basal metabolic rate and airway cell
production of NO and systemic and airway production
of CO may underlie changes in exhaled NO and CO.
Endogenous NO is continuously generated from L-
arginine, through the action of the nitric oxide synthases
including constitutively expressed neuronal and endo-
thelial types and inducible one. The latter isoform has
the greatest activity and can be induced by inﬂammatory
cytokines, endotoxines, and viral infections. NO found
in the exhaled air (ENO) reﬂects mainly enzymatic NO
production in the respiratory tract but, in a much lesser
degree, may be a result of generation of this mediator
through a NOS-independent pathway (from S-nitro-
sothiols) [25]. Nitric oxide, found in the exhaled air,
may originate from the sinuses, stomach, and lower
respiratory tract. Contamination with air from the
sinuses could be prevented during the measurement by
exhalation against a resistance placed in the mouth,
which raises the soft palate and closes the communica-
tion to the rhinopharynx. Gastric NO, even very high, in
healthy subjects does not contaminate exhaled NO, as
the upper and lower esophageal sphincters are closed
[26]. Alteration of ENO by smoking, caffeine, nitrate, or
nitrate-containing foods ingestion [27] should be pre-
Table 2. Exhaled Nitric Oxide (NO) and Carbon Monoxide (CO) in Repeated Measurements in Men
Days 1–6 Days 7–12 Days 13–19 Days 20–25 Days 26–31
NO (ppb) 5.08±1.23 5.19±1.6 5.34±1.2 5.12±1.9 4.9±2.0
CO (ppm) 3.02±0.96 3.3±1.15 2.99±1.9 3.4±2.6 3.15±1.7
No variability either in NO nor CO levels was observed. Mean values±standard deviations are shown
Fig. 1. Changes of exhaled nitric oxide (NO) levels in expired air in
relation to ovarian cycle. Day 1 is the 1st day of menstruation. Mean
values are shown as horizontal bars.
Fig. 2. Changes of exhaled carbon monoxide (CO) levels in relation to
ovarian cycle. Day 1 is the 1st day of menstruation. Mean values are
shown as horizontal bars.
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test (according to the ATS criteria) [28]. In such
conditions, ENO concentration results mainly from the
NO production and its release from the respiratory tract
to the airway lumen and depends on the airﬂow rate
from the distal part of respiratory tract to the mouth [29].
Both may be affected by hormones during the ovarian
cycle. Kirsch et al. [15] have shown that functional
estrogen receptors are expressed in human airway
epithelial cells and endothelial NO synthase activity
more than doubled at 5 min after exposure to physio-
logical concentrations of estrogen [15]. It could be
reﬂected by higher ENO concentrations in midcycle
(preovulation and ovulation phases) where the estrogen
concentration in the blood is the highest. Furthermore,
progesterone increases resting minute ventilation during
the luteal phase by central neural mechanisms [30]a n d
augments ventilatory responses to hypoxemia and hyper-
capnia via an increased sensitivity of chemoreceptors [30–
32]. Increased respiratory rate may result in the fall of
FeNO [33], indicated in the luteal phase of our study. This
may have some functional relevance. Asthma morbidity
may be affected by the ovarian cycle. A study by Eliasson
etal. showed that 33% ofasthmatic women had signiﬁcant
worsening of total pulmonary symptom scores during
either the premenstrual period, the menstrual period, or
both with maximum increase in dyspnea, wheezing, and
chest tightness during the premenstrual period [13]. Fewer
symptoms were reported at midcycle when estrogen levels
are highest. Moreover, estrogen treatment can be a steroid-
sparing therapy in women with refractory asthma [34]. We
observed the lowest levels of exhaled NO in the progesta-
tional phase when asthma symptoms usually worsen
compared with those present in the midcycle. This could
reﬂect a protective effect of NO derived from constitutive
NO synthase in the airways of asthmatic patients.
In contrast to ENO, ECO reﬂects mainly systemic
productionofCOand isclosely relatedtoCOHgb levelsin
the blood. ECO arises from the endogenous enzymatic
degradation of hemoglobin (85%) catalyzed by heme
oxygenase and degradation of myoglobin, catalase, and
cytochromes (15%)[35].Althoughthe alveoli are the main
place for CO elimination, ECO can be contaminated by
carbonmonoxidefromthesinuses[35]. Through induction
of HO-1, endogenous CO production could be increased
by hypoxia, heavy metals, heme, exogenous CO, pro-
inﬂammatory cytokines, hyperglycemia and hormones
[36], and endogenously generated NO [20]. Thus, ECO
may serve as a marker in diabetes [37], cirrhosis [38]
hemoglobinopathies [39]a s t h m a[ 7], cystic ﬁbrosis [8],
bronchiectasis [9], and respiratory tract infections [10]. In
our study, exhaled CO levels were high in the secretory
phase, reaching their highest levels in the premenstrual
phase.Althoughacausativeroleintheincreasedbloodand
hemoglobin loss has been suggested to be the main source
of increased CO production, there is no clear indication as
to the mechanism by which exhaled CO concentration is
highest in the premenstrual phase, as there is no increased
hemoglobin degradation at this time. However, progester-
one may signiﬁcantly induce the expression of HO-1 and
HO-2 mRNAs and HO-1 protein synthesis with subse-
quentCOproductioninhuman myometrium[19].Thishas
been proposed as an endogenous inhibitory mechanism of
myometrial contractility during pregnancy. Since HO-1 is
expressed in airway epithelial cells and macrophages, it is
plausible that increased concentrations of exhaled CO in
the luteal phase are also a result of HO-1 induction by
progesterone.
Furthermore, in our study the lowest exhaled NO
concentrations are associated with the highest CO levels.
Although there are no inverse correlations between both
gases, the lowest NO levels and the highest CO are
observed in the progestational phase of ovarian cycle. CO
can bind to the heme moiety of NOS and thus inhibit NO
production [40]. On the other hand, growing evidence
suggests that NO donors and NO itself induces expression
of HO-1 in smooth muscle cell lines [40]. This is of a great
importance in the sustained production of NO in oxidative
stress providing an endogenous defense mechanism
against reactive nitrogen species [41]. These two phenom-
ena could reﬂect a physiologic pattern of exhaled NO and
CO production. CO could be an inhibitor of airway
inducible NO synthase, and this is why the lowest NO
levels are observed when CO reaches its highest concen-
trations. On the other hand, the lowest CO levels should be
associated with the highest of those exhaled NO, but this
wasnotobservedinourstudy.Thelowestlevelsofexhaled
COwereobservedinthe ﬁrst days offollicular phase when
NO is far from its highest values. This could indicate that
the regulatory network for NO and CO production in the
airways is likely to be more complex.
CONCLUSIONS
Both exhaled NO and CO are increasingly used as
noninvasive indices of airway inﬂammation and may be
useful in monitoring airway diseases. It is important to
take into account the effect of the ovarian cycle on these
measurements. Repeated measurements of exhaled NO
557 Exhaled NO and CO During Ovarian Cycleand CO in women should be performed at the same time
as the ovarian cycle.
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